Literature DB >> 26093588

[Guidelines for the use of second-generation long-acting antipsychotics].

Marek Jarema1, Adam Wichniak2, Dominika Dudek3, Jerzy Samochowiec4, Przemysław Bieńkowski5, Janusz Rybakowski6.   

Abstract

Long-acting injectable antipsychotics constitute a valuable alternative for the treatment of psychotic disorders, mainly schizophrenia. They assure a more stable drug level, improve treatment compliance, and increase the chances for favorable and long-lasting improvement. Additionally, the long-acting second-generation antipsychotics combine the values of long-acting injectable drugs with the values of atypical antipsychotics. Four second generation long-acting antipsychotics have been described: risperidone, olanzapine, aripiprazole and paliperidone. The indications for their use, treatment strategy, tolerance, and potential interactions are discussed.

Entities:  

Keywords:  guidelines for use; long-acting antipsychotics; schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26093588     DOI: 10.12740/PP/39370

Source DB:  PubMed          Journal:  Psychiatr Pol        ISSN: 0033-2674            Impact factor:   1.657


  3 in total

1.  Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1.

Authors:  Martha Sajatovic; Ruth Ross; Susan N Legacy; Christoph U Correll; John M Kane; Faith DiBiasi; Heather Fitzgerald; Matthew Byerly
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-08       Impact factor: 2.570

2.  Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia.

Authors:  Anna Michalczyk; Justyna Pełka-Wysiecka; Jolanta Kucharska-Mazur; Michał Wroński; Błażej Misiak; Jerzy Samochowiec
Journal:  Ann Gen Psychiatry       Date:  2020-06-17       Impact factor: 3.455

3.  Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.

Authors:  Tingjian Yan; Mallik Greene; Eunice Chang; Ann Hartry; Maëlys Touya; Michael S Broder
Journal:  Adv Ther       Date:  2018-09-11       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.